Salta alla navigazione principale Salta alla ricerca Salta al contenuto principale

Rasch analysis of clinical outcome measures in spinal muscular atrophy

  • Stefan J. Cano
  • , Anna Mayhew
  • , Allan M. Glanzman
  • , Kristin J. Krosschell
  • , Kathryn J. Swoboda
  • , Marion Main
  • , Birgit F. Steffensen
  • , Carole Bérard
  • , Françoise Girardot
  • , Christine A.M. Payan
  • , Eugenio Maria Mercuri
  • , Elena Mazzone
  • , Bakri Elsheikh
  • , Julaine Florence
  • , Linda S. Hynan
  • , Susan T. Iannaccone
  • , Leslie L. Nelson
  • , Shree Pandya
  • , Michael Rose
  • , Charles Scott
  • Reza Sadjadi, Mackensie A. Yore, Cynthia Joyce, John T. Kissel
  • Peninsula Medical School Universities of Exeter and Plymouth
  • Newcastle University
  • University of Pennsylvania
  • Northwestern University
  • University of Utah
  • Great Ormond Street Hospital for Children
  • Rehabiliterings Center for Muskelsvind
  • Centre Hospitalier, France
  • Assistance publique – Hôpitaux de Paris
  • Ohio State University
  • Washington University St. Louis
  • University of Texas Southwestern Medical Center
  • University of Rochester
  • King's College Hospital
  • CBS
  • University of Virginia
  • Spinal Muscular Atrophy Foundation
  • Center for Microbial Pathogenesis

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

Introduction: Trial design for SMA depends on meaningful rating scales to assess outcomes. In this study Rasch methodology was applied to 9 motor scales in spinal muscular atrophy (SMA). Methods: Data from all 3 SMA types were provided by research groups for 9 commonly used scales. Rasch methodology assessed the ordering of response option thresholds, tests of fit, spread of item locations, residual correlations, and person separation index. Results: Each scale had good reliability. However, several issues impacting scale validity were identified, including the extent that items defined clinically meaningful constructs and how well each scale measured performance across the SMA spectrum. Conclusions: The sensitivity and potential utility of each SMA scale as outcome measures for trials could be improved by establishing clear definitions of what is measured, reconsidering items that misfit and items whose response categories have reversed thresholds, and adding new items at the extremes of scale ranges. Muscle Nerve 49:422-430, 2014.
Lingua originaleInglese
pagine (da-a)422-430
Numero di pagine9
RivistaMUSCLE & NERVE
Volume49
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Rasch analysis
  • clinical trials
  • motor neuron disease
  • outcome measures
  • spinal muscular atrophy

Fingerprint

Entra nei temi di ricerca di 'Rasch analysis of clinical outcome measures in spinal muscular atrophy'. Insieme formano una fingerprint unica.

Cita questo